Linear Piezoelectric Low Intensity Shockwave Treatment (LI-SWT) for the Treatment of Erectile Dysfunction in PDE5i Non Responder
10. september 2026 oppdatert av: HUNG PUI LONG WILSON, The University of Hong Kong
Linear Piezoelectric Low Intensity Shockwave Treatment (LI-SWT) for the Treatment of Erectile Dysfunction in PDE5i Non Responder: A Randomized-Controlled Trial
The goal of this clinical trial is to assess the efficacy and safety of linear piezoelectric Li-SWT for erectile dysfunction patients who have poor treatment respond from PDE5i oral treatment. Participants will be randomised to either receive 4 cycles, once per week, of Li-SWT treatment on the penis or the Sham group, where the treatment appears to be identical but the shockwave machine is deactivated. Investigators will compare the before and after treatment erectile function using the IIEF questionnaire of the two groups 1 month after treatment to assess the treatment outcome. After that, the Sham group patient would be offered to receive compensatory Li-SWT treatment and their post treatment response will be assessed.
All the patients completing the Li-SWT treatment will be followed up at 6 and 12 months to assess the efficacy and adverse events.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
40
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Dr Hung, MBBS
- Telefonnummer: 852-22554852
- E-post: hpl826@ha.org.hk
Studiesteder
-
-
-
Hong Kong, Hong Kong
- Rekruttering
- Queen Mary Hospital
-
Ta kontakt med:
- Dr Hung, MBBS
- Telefonnummer: 852-22554852
- E-post: hpl826@ha.org.hk
-
Hovedetterforsker:
- Pui Long Wilson Hung, MBBS
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Male
- Age 30-80 years
- ED for at least 6 months, defined by IIEF-EF score 8-21 (moderate - mild)
- Sexually active in a stable, heterosexual relationship of more than 3 months duration.
- Agree to comply with all study related tests/procedures
- Morning serum testosterone >12nmol/L
- Inadequate response after at least 4 attempts using highest tolerated PDE5i
Exclusion Criteria:
- Previous penile surgery (e.g. penile lengthening, penile cancer surgery, penile plication, grafting, penile implant).
- Previous history of priapism or penile fracture
- Morning serum testosterone level <12nmol/L
- Current or previous hormone usage, other than prescribed testosterone, clomiphene or thyroid medication. (Subjects with prior or current use of hormonal treatment for prostate cancer are also excluded
- Psychogenic ED as determined by study investigator
- Anatomical (Peyronie's Disease or penile curvature) abnormality
- Neurological disease (Parkinson's, spinal cord injury)
- Anti-coagulation therapy and/or INR >1.5 (Patients on aspirin are eligible) 7
- Current or prior history of sexually transmitted disease
- Tumor tissue/Treatment for cancer in the penile or pelvic region in past 5 years
- Electronic devices implanted in the body (e.g. cardiac pacemaker, deep brain stimulator, spinal cord neurostimulator etc.)
- Any other medical conditions or medical history that are deemed unsafe or high risk for the study treatment per investigator's discretion
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LiSWT
LiSWT with 8Hz, 0.16 mJ/mm2, wave focus penetration depth 10-15mm at corpora cavernosa (2000 shock), crus of the penis (2000 shock), Once per week for 4 weeks
|
LiSWT with 8Hz, 0.16 mJ/mm2, wave focus penetration depth 10-15mm at corpora cavernosa (2000 shock), crus of the penis (2000 shock), Once per week for 4 weeks
|
|
Sham-komparator: Sham
Sham comparator with the device deactivated
|
Sham low-intensity shockwave therapy with device deactivated
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of men with improvement in International Index of Erectile Function (IIEF) score at 1 month after traetment
Tidsramme: 1 month after Sham/LiSWT
|
Total scores range from 5 to 25, where higher scores indicate better erectile function/lower severity of erectile dysfunction.
This outcome measure reports the proportion of participants achieving an improvement in IIEF score compared to baseline.
|
1 month after Sham/LiSWT
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of men meeting the Minimal Clinically Important Difference (MCID) in the International Index of Erectile Function (IIEF) score
Tidsramme: 1 month
|
The International Index of Erectile Function (IIEF) is a self-administered questionnaire used to assess erectile function.Total scores range from 5 to 25, where higher scores indicate better erectile function/lower severity of erectile dysfunction.
This outcome measure reports the proportion of participants achieving a minimal clinically important difference (MCID) in the IIEF-5 score compared to baseline.
|
1 month
|
|
Proportion of men meeting the Minimal Clinically Important Difference (MCID) in the International Index of Erectile Function - Erectile Function (IIEF-EF) domain score at 6 and 12 months after treatment
Tidsramme: 6 and 12 months after treatment
|
IIEF is a self-administered questionnaire used to assess erectile function.
Total scores range from 5 to 25, where higher scores indicate better erectile function/lower severity of erectile dysfunction.
This outcome measure reports the proportion of participants achieving a minimal clinically important difference (MCID) in the IIEF-5 score compared to baseline.
|
6 and 12 months after treatment
|
|
Erectile hardness score (EHS) at 1,6, 12 months after treatment
Tidsramme: 1, 6, 12 months after LiSWT treatment
|
vertical score assessing penile hardness on a 4-point single-item scale ranging from 1 to 4, where 1 indicates "penis is larger, but not hard" and 4 indicates "penis is completely hard and fully rigid."
Higher scores indicate better erectile function/rigidity.
|
1, 6, 12 months after LiSWT treatment
|
|
Side effects and safety profile
Tidsramme: From initiation of first Sham/LiSWT treatment until 12 months after the last LiSWT treatment
|
e.g.
tolerability, pain using the visual analogue scale, bleeding, bruising, penile plaque, penile deformity Safety and tolerability will be evaluated by recording the incidence, severity, and type of all treatment-related adverse events.
Pain will be assessed using a Visual Analogue Scale (VAS), a single-item numeric scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate greater pain intensity.
Specific adverse events evaluated include penile pain, bleeding, bruising, formation of penile plaque, and penile deformity.
|
From initiation of first Sham/LiSWT treatment until 12 months after the last LiSWT treatment
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
7. januar 2026
Primær fullføring (Antatt)
31. desember 2026
Studiet fullført (Antatt)
31. mars 2027
Datoer for studieregistrering
Først innsendt
24. juni 2026
Først innsendt som oppfylte QC-kriteriene
10. september 2026
Først lagt ut (Faktiske)
15. september 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
10. september 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LiSWTED
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .